Marrone Bio Innovations, Inc. (MBII) financial statements (2021 and earlier)
Company profile
| Business Address |
1540 DREW AVENUE DAVIS, CA 95618 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 287 - Agricultural Chemicals (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6 | 8 | 9 | 14 | 18 | 21 | 23 | ||
| Cash and cash equivalents | 6 | 8 | 9 | 14 | 18 | 21 | 23 | ||
| Restricted cash and investments | 0 | 0 | |||||||
| Receivables | 6 | 7 | 7 | 9 | 3 | 3 | 5 | ||
| Inventory, net of allowances, customer advances and progress billings | 8 | 9 | 8 | 8 | 8 | 9 | 9 | ||
| Inventory | 8 | 9 | 8 | 8 | 8 | 9 | 9 | ||
| Other undisclosed current assets | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||
| Total current assets: | 22 | 26 | 27 | 31 | 30 | 34 | 38 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 5 | 5 | 5 | 5 | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 13 | 13 | 14 | 14 | 15 | 15 | 15 | ||
| Intangible assets, net (including goodwill) | 31 | 32 | |||||||
| Goodwill | 7 | 7 | |||||||
| Intangible assets, net (excluding goodwill) | 24 | 24 | |||||||
| Restricted cash and investments | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
| Other noncurrent assets | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 51 | 52 | 21 | 21 | 16 | 17 | 17 | ||
| TOTAL ASSETS: | 73 | 78 | 47 | 52 | 47 | 51 | 55 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 16 | 17 | 12 | 9 | 9 | 8 | 7 | ||
| Accounts payable | 3 | 2 | 2 | 2 | 2 | 2 | 1 | ||
| Accrued liabilities | 12 | 15 | 10 | 7 | 7 | 6 | 6 | ||
| Deferred revenue | 0 | 0 | 0 | 0 | ✕ | ✕ | ✕ | ||
| Debt | 4 | 7 | 4 | 6 | 2 | 2 | 3 | ||
| Other undisclosed current liabilities | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Total current liabilities: | 21 | 25 | 17 | 16 | 11 | 10 | 10 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 16 | 16 | 16 | 16 | 12 | 12 | 12 | ||
| Long-term debt, excluding current maturities | 12 | 12 | 12 | 12 | 12 | 12 | 12 | ||
| Operating lease, liability | 4 | 4 | 4 | 5 | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 12 | 13 | 10 | 10 | 8 | 8 | 8 | ||
| Deferred revenue | 2 | 2 | 2 | 2 | ✕ | ✕ | ✕ | ||
| Due to related parties | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||
| Other liabilities | 3 | 4 | 1 | 1 | 1 | 1 | 1 | ||
| Other undisclosed noncurrent liabilities | 2 | 3 | 3 | ||||||
| Total noncurrent liabilities: | 28 | 29 | 26 | 27 | 22 | 23 | 23 | ||
| Total liabilities: | 49 | 54 | 44 | 43 | 34 | 32 | 33 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 24 | 25 | 3 | 10 | 13 | 18 | 22 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 344 | 335 | 298 | 297 | 296 | 294 | 293 | ||
| Accumulated deficit | (321) | (311) | (294) | (287) | (283) | (275) | (271) | ||
| Total stockholders' equity: | 24 | 25 | 3 | 10 | 13 | 18 | 22 | ||
| TOTAL LIABILITIES AND EQUITY: | 73 | 78 | 47 | 52 | 47 | 51 | 55 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 7 | 7 | 7 | 9 | 6 | 5 | 6 | |
| Cost of revenue | (3) | (3) | (3) | (4) | (3) | (3) | (3) | |
| Gross profit: | 4 | 4 | 4 | 5 | 3 | 3 | 3 | |
| Operating expenses | (12) | (13) | (10) | (9) | (8) | (7) | (7) | |
| Operating loss: | (8) | (10) | (6) | (4) | (5) | (4) | (4) | |
| Nonoperating expense | (2) | (7) | (0) | (0) | (3) | (0) | (0) | |
| Interest and debt expense | (0) | (0) | (0) | (0) | (2) | (0) | (0) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 1 | |||||||
| Loss from continuing operations before income taxes: | (9) | (17) | (7) | (4) | (10) | (5) | (5) | |
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net loss: | (9) | (17) | (7) | (4) | (10) | (5) | (5) | |
| Other undisclosed net income (loss) attributable to parent | (1) | 0 | 0 | 0 | 2 | 0 | 0 | |
| Net loss available to common stockholders, diluted: | (10) | (16) | (7) | (4) | (8) | (4) | (5) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (9) | (17) | (7) | (4) | (10) | (5) | (5) | |
| Comprehensive loss, net of tax, attributable to parent: | (9) | (17) | (7) | (4) | (10) | (5) | (5) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.